The median progression-free survival (PFS) of platinum plus pemetrexed is 4.2–6.4 months in patients with NSCLC harboring EGFR mutation after tyrosine kinase inhibitor failure [7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.